{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pierson SR"],"funding":["U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","NIA NIH HHS","NIDDK NIH HHS","U.S. Department of Health & Human Services | NIH | National Institute on Aging","NHLBI NIH HHS","U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","NIAAA NIH HHS","U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)","NINDS NIH HHS","NIGMS NIH HHS","U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases"],"pagination":["532-546"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12010729"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(2)"],"pubmed_abstract":["Protein aggregation in brainstem nuclei is thought to occur in the early stages of Alzheimer's disease (AD), but its specific role in driving prodromal symptoms and disease progression is largely unknown. The dorsal raphe nucleus (DRN) contains a large population of serotonin (5-hydroxytryptamine; 5-HT) neurons that regulate mood, reward-related behavior, and sleep, which are all disrupted in AD. We report here that tau pathology is present in the DRN of individuals 25-80 years old without a known history of dementia, and its prevalence was comparable to the locus coeruleus (LC). By comparison, fewer cases were positive for other pathological proteins including α-synuclein, β-amyloid, and TDP-43. To evaluate how early tau pathology impacts behavior, we overexpressed human P301L-tau in the "],"journal":["Molecular psychiatry"],"pubmed_title":["Tau pathology in the dorsal raphe may be a prodromal indicator of Alzheimer's disease."],"pmcid":["PMC12010729"],"funding_grant_id":["T32 HL007638","R01 AA028931","R01 AG070841),","T32 GM067795","R01 AG070841","R01 NS136448","K23 NS109284","T32 DK112751"],"pubmed_authors":["Fiock KL","Aldridge G","Balasubramanian N","Deniz K","Hefti MM","Reinhardt J","Khan KM","Lee G","Cooper BJ","Betters R","Hunter ML","Williamsen HR","Wang R","Marcinkiewcz CA","James TD","Pierson SR"],"additional_accession":[]},"is_claimable":false,"name":"Tau pathology in the dorsal raphe may be a prodromal indicator of Alzheimer's disease.","description":"Protein aggregation in brainstem nuclei is thought to occur in the early stages of Alzheimer's disease (AD), but its specific role in driving prodromal symptoms and disease progression is largely unknown. The dorsal raphe nucleus (DRN) contains a large population of serotonin (5-hydroxytryptamine; 5-HT) neurons that regulate mood, reward-related behavior, and sleep, which are all disrupted in AD. We report here that tau pathology is present in the DRN of individuals 25-80 years old without a known history of dementia, and its prevalence was comparable to the locus coeruleus (LC). By comparison, fewer cases were positive for other pathological proteins including α-synuclein, β-amyloid, and TDP-43. To evaluate how early tau pathology impacts behavior, we overexpressed human P301L-tau in the ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-03-17T15:29:56.592Z","creation":"2025-08-16T03:06:55.792Z"},"accession":"S-EPMC12010729","cross_references":{"pubmed":["39143322"],"doi":["10.1038/s41380-024-02664-9"]}}